Abstract | PURPOSE: EXPERIMENTAL DESIGN:
TroVax was administered to 17 patients with metastatic colorectal cancer. In total, 11 patients were considered to be evaluable for assessment of immunologic responses having received a total of six injections of TroVax, administered before, during, and following completion of chemotherapy. Antibody and cellular responses specific for 5T4 and MVA were monitored throughout the study. RESULTS: Administration of TroVax alongside 5-fluorouracil, folinic acid, and oxaliplatin was safe and well tolerated with no serious adverse events attributed to TroVax. Ten of the 11 evaluable patients mounted 5T4-specific antibody responses with titers ranging from 10 to >1,000. IFNgamma enzyme-linked immunospot responses specific for 5T4 were detected in 10 patients with precursor frequencies exceeding 1 in 1,000 peripheral blood mononuclear cells in 4 patients. Of the 11 evaluable patients, 6 had complete or partial responses. 5T4-specific immune responses, but not MVA-specific immune responses, correlated with clinical benefit. CONCLUSIONS: Potent 5T4-specific cellular and/or antibody responses were induced in all evaluable patients and were still detectable during the period in which chemotherapy was administered. These results suggest that TroVax can be added to chemotherapy regimens without any evidence of enhanced toxicity or reduced immunologic efficacy and may provide additional clinical benefit.
|
Authors | Richard Harrop, Noel Drury, William Shingler, Priscilla Chikoti, Irina Redchenko, Miles W Carroll, Susan M Kingsman, Stuart Naylor, Alan Melcher, Joanna Nicholls, Harpreet Wassan, Nagy Habib, Alan Anthoney |
Journal | Clinical cancer research : an official journal of the American Association for Cancer Research
(Clin Cancer Res)
Vol. 13
Issue 15 Pt 1
Pg. 4487-94
(Aug 01 2007)
ISSN: 1078-0432 [Print] United States |
PMID | 17671134
(Publication Type: Clinical Trial, Phase II, Journal Article)
|
Chemical References |
- Cancer Vaccines
- Membrane Glycoproteins
- Organoplatinum Compounds
- TroVax
- Vaccines, DNA
- trophoblastic glycoprotein 5T4, human
- Oxaliplatin
- Fluorouracil
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Cancer Vaccines
(immunology, therapeutic use)
- Colorectal Neoplasms
(diagnostic imaging, immunology, pathology, therapy)
- Enzyme-Linked Immunosorbent Assay
- Female
- Fluorouracil
(administration & dosage)
- Humans
- Liver Neoplasms
(diagnostic imaging, immunology, secondary, therapy)
- Lymphatic Metastasis
- Male
- Membrane Glycoproteins
(immunology)
- Middle Aged
- Organoplatinum Compounds
(administration & dosage)
- Oxaliplatin
- Tomography, X-Ray Computed
- Vaccination
- Vaccines, DNA
- Vaccinia virus
(genetics)
|